1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Osteoarthritis Drugs Market 

4. Market Overview
     4.1. Overview
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Market Dynamics
            4.3.1. Drivers
            4.3.2. Restraints
            4.3.3. Opportunities
     4.4. Global Osteoarthritis Drugs Market Analysis and Forecast, 2016–2026
            4.4.1. Global Osteoarthritis Drugs Market Revenue Projections (US$ Mn)
     4.5. Porter’s Five Force Analysis

5. Market Outlook
     5.1.Disease Prevalence & Incidence Rate globally with key countries
     5.2.Regulatory Scenario by Region/globally
     5.3.Pipeline Analysis

6. Global Osteoarthritis Drugs Market Analysis and Forecast, by Drug Class 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Global Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
            6.3.1. Corticosteroids
            6.3.2. NSAIDs & others
            6.3.3. Viscosupplementation Agents 
     6.4. Global Osteoarthritis Drugs Market Attractiveness by Drug Class 

7. Global Osteoarthritis Drugs Market Analysis and Forecast, by Route of Administration 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Global Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
            7.3.1. Oral  
            7.3.2. Parenteral 
            7.3.3. Topical 
     7.4. Global Osteoarthritis Drugs Market Attractiveness, by Route of Administration 

8. Global Osteoarthritis Drugs Market Analysis and Forecast, by Distribution Channel 
     8.1. Introduction & Definition
     8.2. Key Findings / Developments
     8.3. Global Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            8.3.1. Hospital pharmacies 
            8.3.2. Retail pharmacies 
            8.3.3. Online pharmacies 
     8.4. Global Osteoarthritis Drugs Market Attractiveness, by Distribution Channel 

9. Global Osteoarthritis Drugs Market Analysis and Forecast, by Region
     9.1. Key Findings
     9.2. Global Osteoarthritis Drugs Market Value Forecast, by Region
            9.2.1. North America 
            9.2.2. Europe 
            9.2.3. Asia Pacific 
            9.2.4. Latin America 
            9.2.5. Middle East & Africa 
     9.3. Global Osteoarthritis Drugs Market Attractiveness, by Region

10. North America Osteoarthritis Drugs Market Analysis and Forecast
     10.1. Introduction
     10.2. North America Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
            10.2.1.Corticosteroids
            10.2.2. NSAIDs & Others
            10.2.3.Viscosupplementation agents 
     10.3. North America Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
            10.3.1. Oral  
            10.3.2. Parenteral 
            10.3.3. Topical 
     10.4. North America Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            10.4.1. Hospital pharmacies 
            10.4.2. Retail pharmacies 
            10.4.3. Online pharmacies 
     10.5. North America Osteoarthritis Drugs Market Value Forecast, by Country, 2016–2026
            10.5.1. US
            10.5.2. Canada 
     10.6. North America Osteoarthritis Drugs Market Attractiveness Analysis 
            10.6.1. By Drug Class 
            10.6.2. By Route of Administration 
            10.6.3. By Distribution Channel 
            10.6.4. By Country

11. Europe Osteoarthritis Drugs Market Analysis and Forecast
     11.1.Introduction
     11.2. Europe Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
            11.2.1. Corticosteroids
            11.2.2. NSAIDs & Others
            11.2.3. Viscosupplementation agents 
     11.3. Europe Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
            11.3.1. Oral  
            11.3.2. Parenteral 
            11.3.3. Topical 
     11.4. Europe Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            11.4.1. Hospital pharmacies 
            11.4.2. Retail pharmacies 
            11.4.3. Online pharmacies 
     11.5. Europe Osteoarthritis Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
            11.5.1. Germany
            11.5.2. France
            11.5.3. U.K.
            11.5.4. Italy
            11.5.5. Spain
            11.5.6. Rest of Europe
     11.6. Europe Osteoarthritis Drugs Market Attractiveness Analysis 
            11.6.1. By Drug Class 
            11.6.2. By Route of Administration 
            11.6.3. By Distribution Channel 
            11.6.4. By Country/Sub-region

12. Asia Pacific Osteoarthritis Drugs Market Analysis and Forecast
     12.1.Introduction
     12.2. Asia Pacific Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
            12.2.1. Corticosteroids
            12.2.2. NSAIDs & Others
            12.2.3. Viscosupplementation agents 
     12.3. Asia Pacific Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
            12.3.1. Oral  
            12.3.2. Parenteral 
            12.3.3. Topical 
     12.4. Asia Pacific Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            12.4.1. Hospital pharmacies 
            12.4.2. Retail pharmacies 
            12.4.3. Online pharmacies 
     12.5. Asia Pacific Osteoarthritis Drugs Market Value Forecast by Country/Sub-region, 2016–2026
            12.5.1. Japan
            12.5.2. China
            12.5.3. India
            12.5.4. Australia & New Zealand
            12.5.5. Rest of Asia Pacific
     12.6. Asia Pacific Osteoarthritis Drugs Market Attractiveness Analysis 
            12.6.1. By Drug Class 
            12.6.2. By Route of Administration 
            12.6.3. By Distribution Channel 
            12.6.4. By Country/Sub-region

13. Latin America Osteoarthritis Drugs Market Analysis and Forecast
     13.1.Introduction
     13.2. Latin America Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
            13.2.1. Corticosteroids
            13.2.2. NSAIDs & Others
            13.2.3. Viscosupplementation agents 
     13.3. Latin America Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
            13.3.1. Oral  
            13.3.2. Parenteral 
            13.3.3. Topical 
     13.4. Latin America Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            13.4.1. Hospital pharmacies 
            13.4.2. Retail pharmacies 
            13.4.3. Online pharmacies 
     13.5. Latin America Osteoarthritis Drugs Market Value Forecast, by Country/Sub-region, 2016–2026
            13.5.1. Brazil
            13.5.2. Mexico
            13.5.3. Rest of Latin America
     13.6. Latin America Osteoarthritis Drugs Market Attractiveness Analysis 
            13.6.1. By Drug Class 
            13.6.2. By Route of Administration 
            13.6.3. By Distribution Channel 
            13.6.4. By Country/Sub-region

14. Middle East & Africa Osteoarthritis Drugs Market Analysis and Forecast
     14.1.Introduction
     14.2. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Drug Class, 2016–2026
            14.2.1. Corticosteroids
            14.2.2. NSAIDs & Others
            14.2.3. Viscosupplementation agents 
     14.3. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Route of Administration, 2016–2026
            14.3.1. Oral  
            14.3.2. Parenteral 
            14.3.3. Topical 
     14.4. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Distribution Channel, 2016–2026
            14.4.1. Hospital pharmacies 
            14.4.2. Retail pharmacies 
            14.4.3. Online pharmacies 
     14.5. Middle East & Africa Osteoarthritis Drugs Market Value Forecast, by Country/Sub-regions, 2016–2026
            14.5.1. GCC Countries
            14.5.2. Israel
            14.5.3. South Africa
            14.5.4. Rest of MEA
     14.6. Middle East & Africa Osteoarthritis Drugs Market Attractiveness Analysis 
            14.6.1. By Drug Class 
            14.6.2. By Route of Administration 
            14.6.3. By Distribution Channel 
            14.6.4. By Country

15. Competition Landscape
     15.1. Global Osteoarthritis Drugs Market Player – Competition Matrix (by Tier and Size of companies)
     15.2. Global Osteoarthritis Drugs Market Share Analysis, by Company (2016)
     15.3. Company Profiles
            15.3.1. Horizon Pharma plc. 
                     15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.1.2. Product Portfolio
                     15.3.1.3. SWOT Analysis
                     15.3.1.4. Financial Overview
                     15.3.1.5. Strategic Overview
            15.3.2. Pfizer Inc.
                     15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.2.2. Product Portfolio
                     15.3.2.3. SWOT Analysis
                     15.3.2.4. Financial Overview
                     15.3.2.5. Strategic Overview
            15.3.3. Sanofi 
                     15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.3.2. Product Portfolio
                     15.3.3.3. SWOT Analysis
                     15.3.3.4. Financial Overview
                     15.3.3.5. Strategic Overview
            15.3.4. Anika Therapeutics, Inc.  
                     15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.4.2. Product Portfolio
                     15.3.4.3. SWOT Analysis
                     15.3.4.4. Financial Overview
                     15.3.4.5. Strategic Overview
            15.3.5. Ferring B.V.
                     15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.5.2. Product Portfolio
                     15.3.5.3. SWOT Analysis
                     15.3.5.4. Financial Overview
                     15.3.5.5. Strategic Overview
            15.3.6. Bioventus, Inc. 
                     15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.6.2. Product Portfolio
                     15.3.6.3. SWOT Analysis
                     15.3.6.4. Financial Overview
                     15.3.6.5. Strategic Overview
            15.3.7. Chugai Pharmaceutical Industries Limited  
                     15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.7.2. Product Portfolio
                     15.3.7.3. SWOT Analysis
                     15.3.7.4. Financial Overview
                     15.3.7.5. Strategic Overview
            15.3.8. Alkem Laboratories
                     15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.8.2. Product Portfolio
                     15.3.8.3. SWOT Analysis
                     15.3.8.4. Financial Overview
                     15.3.8.5. Strategic Overview
            15.3.9. Flexion Therapeutics, Inc.  
                     15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.9.2. Product Portfolio
                     15.3.9.3. SWOT Analysis
                     15.3.9.4. Financial Overview
                     15.3.9.5. Strategic Overview
            15.3.10. Zimmer Biomet Holdings, Inc.
                     15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                     15.3.10.2. Product Portfolio
                     15.3.10.3. SWOT Analysis
                     15.3.10.4. Financial Overview
                     15.3.10.5. Strategic Overview

List of Tables

Table 01: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 02: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 03: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 04: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 05: North America Osteoarthritis Drugs Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 06: North America Osteoarthritis Drugs Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 07: North America Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 08: North America Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 09: Europe Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 10: Europe Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 11: Europe Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 12: Europe Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 13: Asia Pacific Osteoarthritis Drugs Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 14: Asia Pacific Osteoarthritis Drugs Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 15: Asia Pacific Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 16: Asia Pacific Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 17: Latin America Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 18: Latin America Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 19: Latin America Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 20: Latin America Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 21: Middle East & Africa Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 22: Middle East & Africa Osteoarthritis Drugs Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 23: Middle East & Africa Osteoarthritis Drugs Value (US$ Mn) Forecast, by Route of Administration, 2016–2026
Table 24: Middle East & Africa Osteoarthritis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026

 

 

List of Figures

Figure 01: Global Osteoarthritis Drugs Market Snapshot
Figure 02: Global Fluid Management Market Value (US$ Mn) and Distribution, by Region, 2017 and 2026
Figure 03: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast, 2016?2026
Figure 04: Global Osteoarthritis Drugs Market Value Share, by Drug Class (2017)
Figure 05: Global Osteoarthritis Drugs Market Value Share, by Route of Administration (2017)
Figure 06: Global Osteoarthritis Drugs Market Value Share, by Distribution Channel (2017)
Figure 07: Global Osteoarthritis Drugs Market Value Share, by Region (2017)
Figure 08: Global Osteoarthritis Drugs Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 09: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Corticosteroids
Figure 10: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Others
Figure 11: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Viscosupplementation Agents
Figure 12: Global Osteoarthritis Drugs Market Attractiveness, by Drug Class, 2018–2026
Figure 13: Global Osteoarthritis Drugs Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 14: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Oral, 2016–2026
Figure 15: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Parenteral, 2016–2026
Figure 16: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Topical, 2016–2026
Figure 17: Global Osteoarthritis Drugs Market Attractiveness, by Route of Administration, 2018–2026
Figure 18: Global Osteoarthritis Drugs Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 19: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2016–2026
Figure 20: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2016–2026
Figure 21: Global Osteoarthritis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2016–2026
Figure 22: Global Osteoarthritis Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 23: Global Osteoarthritis Drugs Market Value Share Analysis, by Region 2017 and 2026
Figure 24: Global Osteoarthritis Drugs Market Attractiveness, by Region, 2018–2026
Figure 25: North America Osteoarthritis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 26: North America Osteoarthritis Drugs Market Value Share (%), by Drug Class, 2017 and 2026
Figure 27: North America Osteoarthritis Drugs Market Attractiveness, by Drug Class, 2018–2026
Figure 28: North America Osteoarthritis Drugs Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 29: North America Osteoarthritis Drugs Market Attractiveness, by Route of Administration, 2018–2026
Figure 30: North America Osteoarthritis Drugs Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 31: North America Osteoarthritis Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 32: North America Osteoarthritis Drugs Market Value Share (%), by Country, 2017 and 2026
Figure 33: North America Osteoarthritis Drugs Market Attractiveness, by Country, 2018–2026
Figure 34: Europe Osteoarthritis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 35: Europe Osteoarthritis Drugs Market Value Share (%), by Drug Class, 2017 and 2026
Figure 36: Europe Osteoarthritis Drugs Market Attractiveness, by Drug Class, 2018–2026
Figure 37: Europe Osteoarthritis Drugs Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 38: Europe Osteoarthritis Drugs Market Attractiveness, by Route of Administration, 2018–2026
Figure 39: Europe Osteoarthritis Drugs Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 40: Europe Osteoarthritis Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 41: Europe Osteoarthritis Drugs Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 42: Europe Osteoarthritis Drugs Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 43: Asia Pacific Osteoarthritis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 44: Asia Pacific Osteoarthritis Drugs Market Value Share (%), by Drug Class, 2017 and 2026
Figure 45: Asia Pacific Osteoarthritis Drugs Market Attractiveness, by Drug Class, 2018–2026
Figure 46: Asia Pacific Osteoarthritis Drugs Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 47: Asia Pacific Osteoarthritis Drugs Market Attractiveness, by Route of Administration, 2018–2026
Figure 48: Asia Pacific Osteoarthritis Drugs Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 49: Asia Pacific Osteoarthritis Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 50: Asia Pacific Osteoarthritis Drugs Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 51: Asia Pacific Osteoarthritis Drugs Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 52: Latin America Osteoarthritis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 53: Latin America Osteoarthritis Drugs Market Value Share (%), by Drug Class, 2017 and 2026
Figure 54: Latin America Osteoarthritis Drugs Market Attractiveness, by Drug Class, 2018–2026
Figure 55: Latin America Osteoarthritis Drugs Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 56: Latin America Osteoarthritis Drugs Market Attractiveness, by Route of Administration, 2018–2026
Figure 57: Latin America Osteoarthritis Drugs Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 58: Latin America Osteoarthritis Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 59: Latin America Osteoarthritis Drugs Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 60: Latin America Osteoarthritis Drugs Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 61: Middle East & Africa Osteoarthritis Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 62: Middle East & Africa Osteoarthritis Drugs Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 63: Middle East & Africa Osteoarthritis Drugs Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 64: Middle East & Africa Osteoarthritis Drugs Market Value Share (%), by Drug Class, 2017 and 2026
Figure 65: Middle East & Africa Osteoarthritis Drugs Market Attractiveness, by Drug Class, 2018–2026
Figure 66: Middle East & Africa Osteoarthritis Drugs Market Value Share (%), by Route of Administration, 2017 and 2026
Figure 67: Middle East & Africa Osteoarthritis Drugs Market Attractiveness, by Route of Administration, 2018–2026
Figure 68: Middle East & Africa Osteoarthritis Drugs Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 69: Middle East & Africa Osteoarthritis Drugs Market Attractiveness, by Distribution Channel, 2018–2026
Figure 70: Global Osteoarthritis Drugs Market Share Analysis, by Company (2017)
Figure 71: Horizon Pharma plc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 72: Horizon Pharma plc. Breakdown of Net Sales, by Region, 2017
Figure 73: Horizon Pharma plc. Breakdown of Net Sales, by Drug, 2017
Figure 74: Horizon Pharma plc. Research & Development Cost (US$ Mn), 2015–2017
Figure 75: Pfizer Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 76: Pfizer Inc. R&D Expenses (US$ Mn), 2014–2017
Figure 77: Sanofi Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
Figure 78: Sanofi Breakdown of Net Sales, by Region, 2017
Figure 79: Sanofi Breakdown of Net Sales, by Business Segment, 2017
Figure 80: Sanofi Research & Development Cost, 2015–2017 (US$ Mn)
Figure 81: Anika Therapeutics, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
Figure 82: Anika Therapeutics, Inc. Breakdown of Net Sales, by Region, 2017
Figure 83: Anika Therapeutics, Inc. Breakdown of Net Sales, by Business Segment, 2017
Figure 84: Anika Therapeutics, Inc. Research & Development Cost, 2015–2017 (US$ Mn)
Figure 85: Chugai Pharmaceutical Co., Limited. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 86: Chugai Pharmaceutical Co., Limited. Breakdown of Net Sales, by Region, 2017
Figure 87: Chugai Pharmaceutical Co., Limited. Breakdown of Net Sales, by Business Segment, 2017
Figure 88: Chugai Pharmaceutical Co., Limited. Research & Development Cost (US$ Mn), 2015–2017
Figure 89: Alkem Laboratories Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 90: Alkem Laboratories Breakdown of Net Sales, by Region, 2017
Figure 91: Alkem Laboratories Breakdown of Net Sales, by Business Segment, 2017
Figure 92:  Alkem Laboratories Research & Development Cost (US$ Mn), 2015–2017
Figure 93: Zimmer Biomet Holdings, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 94:  Zimmer Biomet Holdings, Inc. Breakdown of Net Sales, by Region, 2017
Figure 95:  Zimmer Biomet Holdings, Inc. Breakdown of Net Sales, by Business Segment, 2017
Figure 96:  Zimmer Biomet Holdings, Inc. Research & Development Cost (US$ Mn), 2015–2017